With the takeover of Monsanto, Bayer is also bringing enormous legal risks into the house. According to analysts, that could cost the Dax group billions more. In one case, there is now agreement with US class plaintiffs.
Bayer has reached a settlement with US class plaintiffs in the legal dispute over the allegedly misleading marketing of weed killers with the controversial active ingredient glyphosate. The German agrochemical and pharmaceutical company agreed to pay $ 39.6 million – about 35.8 million euros – according to court documents. The trial is about whether the U.S. seed giant Monsanto, acquired by Bayer for more than $ 60 billion in 2018, has masked health risks on its weed killer Roundup's labels. The agreement with the US plaintiffs also includes certain changes to the labeling of the product. Years of litigation Bayer welcomed the settlement in a statement as a solution to the satisfaction of all parties. The competent court in Kansas City, Missouri, has yet to approve the compromise. The settlement was preceded by litigation in multiple federal jurisdictions for more than two years, but there is no direct connection with the U.S. lawsuit against Bayer for alleged cancer risks from Monsanto weed killers such as Roundup. Here, the settlement negotiations continued, but there is still no certainty about an agreement, the company said. Bayer recently reported that it had faced approximately 48,600 lawsuits in the United States for alleged cancer risks, in which case Bayer had lost the first three lawsuits in the United States and received high damages judgments. However, the group wants to have the guilty verdicts set aside. Comparative talks have been going on behind the scenes under the supervision of US star lawyer Ken Feinberg. Analysts expect an agreement that could cost Bayer around $ 10 billion.